कंपनी का अवलोकन
Arvinas, Inc. operates as a clinical-stage biotechnology enterprise dedicated to the discovery, development, and commercialization of therapies designed to degrade disease-causing proteins through the use of proteolysis targeting chimeras. This company functions within the broader Healthcare sector and the specialized Biotechnology industry, where it leverages proprietary technologies to harness biological mechanisms for therapeutic intervention. The organization employs a workforce of 246 individuals and maintains a market capitalization of $717.39M, while generating annual revenue of $262.60M. These valuation and revenue figures suggest that the company holds a significant position in the biotechnology landscape, reflecting investor confidence in its pipeline despite the inherent risks associated with clinical-stage development. The combination of a substantial cash reserve and a defined revenue stream indicates an entity capable of sustaining operations while advancing its scientific objectives.
वित्तीय स्वास्थ्य
The company reported a revenue of $262.60M over the trailing twelve months, yet recorded a net income of $-80,800,000 and an EBITDA of $-111,900,000. The substantial disparity between positive revenue and negative net income reveals a cost structure characterized by high operational expenditures, which is typical for clinical-stage biotechnology firms but necessitates careful management to achieve profitability. Free cash flow stands at $-89,012,496, indicating that the company is currently burning cash, which limits immediate financial flexibility and reliance on external capital sources or internal reserves. The gross margin is reported at 100.0%, suggesting that the cost of goods sold is negligible relative to revenue, likely due to the nature of biotechnology manufacturing or licensing models. Conversely, the operating margin is -754.7% and the profit margin is -30.8%, highlighting severe operating losses that far exceed the revenue generated, pointing to heavy investment in research and development or general and administrative costs. In terms of solvency, the company holds $685.40M in cash against a debt load of only $8.90M, resulting in a debt-to-equity ratio of 2.05, which presents a complex picture of high leverage relative to equity but extremely low absolute debt exposure. The current ratio of 4.92 demonstrates robust short-term liquidity, indicating that the company possesses nearly five times the current assets needed to cover its current liabilities without immediate distress. Return on Equity is -16.2% and Return on Assets is -7.9%, metrics that reveal that management is currently generating negative returns on the capital invested and assets held, a common characteristic in pre-profitability biotechnology stages but one that signals the need for future efficiency gains.
मूल्यांकन आकलन
The P/E Ratio (TTM) is listed as N/A due to negative earnings, while the Forward P/E is reported at -3.17, implying that analysts project a continued negative earnings trajectory or a specific accounting scenario that results in a negative multiple. The price-to-book ratio stands at 1.63, indicating that the market values the company's equity at a premium of 63% over its book value, reflecting expectations of future value creation from its intellectual property. The price-to-sales ratio is 2.73 and the EV/EBITDA is -0.34, suggesting that valuation is being driven primarily by revenue multiples and asset backing rather than earnings power or cash flow generation. The stock traded between a 52-week high of $14.51 and a 52-week low of $5.90, providing a range within which price discovery has occurred over the past year. The Beta value is 1.98, which signifies that the stock exhibits nearly double the volatility of the broader market, making it highly sensitive to shifts in investor sentiment toward biotechnology and healthcare sectors.
Growth & Income
Revenue growth year-over-year has contracted by -84.0%, while earnings growth is marked as N/A due to the absence of net income. The contraction in revenue suggests a significant decline in sales or licensing deals compared to the prior year, which may be attributed to the cyclical nature of the company's commercialization efforts or specific product lifecycle transitions. Since the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically available for reinvestment, although current losses mean the company must rely on cash reserves rather than retained earnings. The overall growth and income profile is currently defined by revenue contraction and negative returns, indicating a phase of intense capital expenditure rather than income generation or expansion. This profile requires a shift from cash burn to positive cash flow generation to support sustainable long-term growth without further dilution of equity.